Leadership & Staff

Executive Staff

  • David Arons

    David F. Arons, JD

    Interim Chief Executive Officer

    David Arons is currently the Interim Chief Executive Officer of National Brain Tumor Society. He also serves as the National Brain Tumor Society’s Chief Public Policy and Advocacy Officer. He previously served as the Director of Government Relations for the American Cancer Society in Minnesota and was the co-founder and Co-Director of the Center for Lobbying in the Public Interest. He is the author of several books, including Power in Policy: A Funder’s Guide to Advocacy and Civic Participation, Strengthening Nonprofit Advocacy, and A Voice for Nonprofits. He serves on the National Cancer Institute’s Council of Research Advocates and Clinical Trials Advisory Committee.

  • Samm Masterson

    Samantha Masterson

    Chief Advancement Officer

    Samantha (Samm) Masterson is National Brain Tumor Society’s Chief Advancement Officer. In this role, Mrs. Masterson works directly with the Chief Executive Officer to provide vision, strategy and leadership to National Brain Tumor Society’s Events, Marketing Communications, and Development functions. Mrs. Masterson is a proven fundraiser, community builder, and manager of human capital. Previously, she served in leadership, development, and marketing communications positions for prominent for-profit and non-profit organizations, such as the American Liver Foundation, The TJX Companies Inc., March of Dimes, and Alternatives Unlimited, Inc.

  • Maryann Morgan

    Maryann Morgan

    Chief Operating Officer

    Maryann Morgan joined the National Brain Tumor Society in 2015 as Chief of Staff. Reporting directly to the Chief Executive Officer, Maryann is responsible for overseeing the operational, administrative, and support functions of the organization, including IT/IS, human resources, as well as office and facilities management. Additionally, Maryann provides strategic leadership and executive management of the organization’s strategic planning process. Maryann is a certified project management professional with expertise in project delivery, organizational leadership, executive and Board communications, and personnel management. Prior to joining the National Brain Tumor Society, Maryann served as Executive and Project Leader to the Office of the President and Office of Institutional Advancement and Marketing Communications at Morehouse School of Medicine.

  • Carrie Treadwell

    Carrie Treadwell

    Chief Research Officer

    Carrie Treadwell serves as the Chief Research Officer at the National Brain Tumor Society, and President of the Cure GBM, LLC and Pediatric Cancer Cure, LLC. In these roles, she interacts with leading researchers and institutions to guide the development and success of key research initiatives including management of Defeat GBM Research Collaborative and Project Impact’s Defeat Pediatric HGG Research Collaborative. Carrie currently serves on the Boards of Students Supporting Brain Tumor Research and Gray Matters Foundation, as well as co-Chairs the Global Adaptive GBM Trial Patient Advocacy Committee. She also serves as the patient advocate for the National Cancer Institute’s Brain Tumor SPORE Program.

  • antonellis

    Michael Antonellis

    National Director of Marketing Communications

    Michael Antonellis is the National Director of Marketing Communications at the National Brain Tumor Society. Mr. Antonellis is an executive staff member and plays a key role within the advancement team by developing, directing and leading marketing strategy and communications programs for internal and external marketing, promotion and branding. He leads campaigns to drive public awareness and brand recognition, build deeper engagement and loyalty from volunteers and donors, and promote organization-centric fundraising and research/clinical trial education. He previously served as Director of Marketing & Communications at Harte Hanks and has held senior communications positions at VISTAGY (now Siemens) and Lois Paul & Partners.

  • strenger

    Craig Strenger

    National Director of Field Operations

    Craig Strenger is the National Director of Field Operations for the National Brain Tumor Society. In this executive role, Mr. Strenger is responsible for strategic field planning, Strategic corporate partnerships as well as national event fundraising, event structure development, budget creation, and training for volunteer management and sponsorship solicitation. He manages and leads a team of extremely talented regional directors that build and manage impactful events and community fundraisers. He has previously held executive positions at Penster Consulting, Cystic Fibrosis Foundation, American Diabetes Association and the Muscular Dystrophy Association.

  • Nance

    Wendi Nance

    National Development Officer

    Wendi Nance serves as the National Brain Tumor Society’s National Development Officer and oversees development strategy and execution for the organization’s health care platform and the Cure GBM and Pediatric Cancer Cure LLCs. Ms. Nance is a senior-level development professional, who most recently served as the Associate Vice President of Institutional Advancement at the Morehouse School of Medicine (MSM). She has also served as the CEO of a South Carolina chapter of the YWCA, and is an active participant on several boards and committees in South Carolina.

Back to top

Board of Directors

Officers

  • Michael Nathanson, JD, LLM

    Michael Nathanson, JD, LLM

    Chair

    Michael Nathanson is the Chair of the National Brain Tumor Society Board of Directors. He is also the Chief Executive Officer, President, and Chairman of The Colony Group, a leading independent wealth management company. He has been on the National Brain Tumor Society’s Board of Directors since 2011. He has been named five times by Barrons as one of the top 100 independent financial advisors in the nation. Mr. Nathanson has been living with a brain tumor since 2000.

  • CORD SCHLOBOHM, DMD

    Cord Schlobohm, DMD

    Vice Chair

    Cord Schlobohm, DMD is the Vice Chair of the National Brain Tumor Society Board of Directors. He has been a practicing dentist in Bethesda, MD for over 25 years. Dr. Schlobohm became involved with the National Brain Tumor Society after losing his daughter to a brain tumor. He recently served as a patient advocate on the peer-reviewed Cancer Research Program of the Department of Defense, and has spoken on NPR on behalf of the National Brain Tumor Society.

  • MICHAEL CORKIN

    Michael Corkin

    Treasurer

    Michael Corkin is the Treasurer of the National Brain Tumor Society Board of Directors. He is also the President and Owner of Corkin Insurance Company, based in Newton, Massachusetts. He initially became involved with the Organization after his daughter was diagnosed and successfully operated on for a brain tumor 20 years ago. He is also a leading fundraiser for the Boston Brain Tumor Ride and in recent years served as the event co-chair.

  • Sarah Durham

    Sarah Durham

    Clerk
    Sarah Durham is the Clerk of the National Brain Tumor Society Board of Directors. She is the Principal and Founder of Big Duck, a communications firm that works exclusively with nonprofits to help reach supporters, build awareness, and raise money. She was named a top fundraiser under 40 by Fundraising Success in 2006, and one of the most influential women in technology by Fast Company in 2010.

Board Members

  • Jeffrey Kolodin, Chairman Emeritus
  • Kristen Campana, Esq.
  • Michael Durbin
  • John Frishkopf
  • Richard Genderson
  • Ken Grey
  • Sheila Killeen
  • Chandri Navarro, Esq.
  • Susan Pannullo, MD
  • Alison Ross, Esq.
  • Stephen T. Sadler, JD
  • Rabbi Eric B. Wisnia

Honorary Board Members

  • G. Bonnie Feldman
  • Steve Karol
  • Scott Memmott, Esq.
  • Charles B. Wilson, MD

Back to top

Advisors

Industry Advisory Board

  • Joanne Smith-Farrell, PhD
    Merck & Co.
  • Michael Nathanson, JD
    The Colony Group
  • Skip Irving, MBA
    Health Advances
  • Michael Gutch, PhD
    MedImmune Ventures
  • Richard Gaynor, MD
    Eli Lilly and Company
  • Brian Gallagher, Jr., PhD
    SR One/GlaxoSmithKline
  • Neil Exter, MBA
    Third Rock Ventures
  • Giulio Draetta, MD, PhD
    UT MD Anderson Cancer Center
  • Bruce Booth, PhD
    Atlas Venture
  • Louis Beardell, Jr., JD, MBA
    Morgan, Lewis & Bockius LLP
  • Lauren Abrey, MD
    Genentech / Roche

Medical Advisory Board

  • Jeffrey Wefel, PhD
    The University of Texas MD Anderson Cancer Center
  • Liz Salmi
    The Liz Army
  • Jeffrey Raizer, MD
    Northwestern Memorial Hospital
  • Scott Pomeroy, MD, PhD
    Boston Children’s Hospital
  • Susan Pannullo, MD
    New York-Presbyterian Hospital/Weil Cornell Medical College
  • Gigi MacMillan
    We Can Pediatric Brain Tumor Network
  • Michelle Lucas, MSW, LSW
    Massachussetts General Hospital
  • Glen Lesser, MD
    Wake Forest University Medical Center
  • Mark Gilbert, MD
    The University of Texas MD Anderson Cancer Center
  • Amar Gajjar, MD
    St. Jude Children’s Research Hospital
  • Sherry Fox, PhD, RN, CNRS
    Bon Secours Cancer Institute
  • Paul Fisher, MD
    Stanford University Medical Center
  • Timothy Cloughesy, MD, Vice Chair
    University of California, Los Angeles
  • Terri S. Armstrong, PhD, NP
    The University of Texas MD Anderson Cancer Center
  • Dr. Patrick Wen, MDDana Farber Cancer Institute (Chair)
  • Dr. Stephen Brem, MDUniversity of Pennsylvania

Public Policy Advisory Committee

  • Eric Wenger
    Microsoft Corp.
  • Max Wallace, JD
    Accelerate Brain Cancer Cure
  • BethAnn Telford
    Team BT
  • Cord Schlobohm, DMD
  • Chandri Navarro, JD
    Hogan Lovells US LLP
  • Scott Memmott, Esq. Chair
    Morgan, Lewis & Bockius LLP
  • Richard Hamburg, MPA
    Trust for America’s Health
  • James “JD” Derderian
    The Stanton Park Group

Scientific Advisory Council

  • Jean Zhao, PhD
    Dana-Farber Cancer Institute
  • Forest M. White, PhD
    Massachusetts Institute of Technology
  • Evan Snyder, MD, PhD
    Sanford Burnham Medical Research Institute
  • John Sampson, MD, PhD
    Duke University Medical Center
  • Paul Mischel, MD
    University of California, Los Angeles
  • Linda Liau, MD, PhD
    University of California, Los Angeles
  • Ching Lau, MD, PhD
    Texas Children’s Cancer Center
  • Robert Jenkins, MD, PhD
    Mayo Clinic
  • C. David James, PhD
    University of California, San Francisco
  • Candece Gladson, MD
    Cleveland Clinic
  • G. Yancey Gillespie, PhD
    University of Alabama at Birmingham
  • Frank Furnari, PhD
    University of California, San Diego
  • David Eisenstat, MD, MA, FRCPC
    University of Alberta
  • Joseph Costello, PhD
    University of California, San Francisco
  • Suzanne Baker, PhD
    St. Jude Children’s Research Hospital

Strategic Scientific Advisory Council

  • W.K. Alfred Yung, MD
    The University of Texas MD Anderson Cancer Center
  • William C. Hahn, MD, PhD
    Dana-Farber Cancer Institute
  • Richard B. Gaynor, MD
    Eli Lilly and Company
  • George D. Demetri, MD
    Dana-Farber Cancer Institute
  • Webster Cavenee, PhD
    Ludwig Institute for Cancer Research, San Diego
  • Darell D. Bigner, MD, PhD
    Duke University
  • Mitchel S. Berger, MD
    University of California, San Francisco
  • Anna Barker, PhDArizona State University

Scientific Policy Committee

  • W.K. Alfred Yung, MD
    The University of Texas MD Anderson Cancer Center
  • Susan Pannullo, MD
    New York-Presbyterian Hospital/Weil Cornell Medical College
  • Steven Brem, MD
    University of Pennsylvania, Perelman School of Medicine
  • Patrick Wen, MD
    Dana-Farber Cancer Institute
  • Linda M. Liau, MD, PhD
    University of California, Los Angeles
  • Kenneth D. Aldape, MD
    The University of Texas MD Anderson Cancer Center
  • Jan Buckner, MD
    Mayo Clinic
Share